Entospletinib (GS-9973)

Mechanism of action

Spleen tyrosine kinase (SYK) inhibitor

Preliminary data

CLL

1. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed

Also known as

• Code name: GS-9973